Glucosamine hydrochloride for the treatment of osteoarthritis symptoms by Fox, Beth Anne & Stephens, Mary M
© 2007 Fox and Stephens publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Interventions in Aging 2007:2(4) 599–604 599
REVIEW




East Tennessee State University, 
Family Physicians of Kingsport, 
Kingsport, TN, USA
Correspondence: Beth Anne Fox
East Tennessee State University, Family 
Physicians of Kingsport, 201 Cassel Drive, 
Kingsport, Tennessee 37660, USA
Tel +1 423 245 9623
Fax +1 423 245 9631
Email foxba@etsu.edu
Abstract: Osteoarthritis is the most common arthritis in the world. It affects millions of people 
with age being the greatest risk factor for developing the disease. The burden of disease will 
worsen with the aging of the world’s population. The disease causes pain and functional dis-
ability. The direct costs of osteoarthritis include hospital and physician visits, medications, and 
assistive services. The indirect costs include work absences and lost wages. Many studies have 
sought to ﬁ  nd a therapy to relieve pain and reduce disability. Glucosamine hydrochloride (HCl) 
is one of these therapies. There are limited studies of glucosamine HCl in humans. Although 
some subjects do report statistically signiﬁ  cant improvement in pain and function from products 
combining glucosamine HCl and other agents, glucosamine HCl by itself appears to offer little 
beneﬁ  t to those suffering from osteoarthritis.
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Osteoarthritis (OA) is the most common arthritis in the world. It is characterized by 
degeneration of joint cartilage which can result in bony remodeling and synovitis. 
The diagnosis is primarily a clinical one based on history and physical examination 
ﬁ  ndings. The need for radiographic ﬁ  ndings to conﬁ  rm the diagnosis is controversial 
since the degree of pain does not correlate to the severity of disease radiographically 
(Hannan et al 2000). The hip and knee joints are most commonly involved; however, 
the shoulders, hands, and back are also frequently affected. Those afﬂ  icted with this 
condition present with pain, morning stiffness of less than an hour with progressive 
improvement during the day, and disability due to loss of function and with an inability 
to perform routine daily activities.
Burden of suffering
In 2000, an estimated 9.6% of men and 18% of women over 60 had symptomatic OA 
(Woolf and Pﬂ  eger 2003). With age being the greatest risk factor for acquiring 
OA, the burden of disease can only worsen. By 2050, the over-60 population in Europe 
is estimated to reach about 33% of the population and in North America about 27% of 
the population. The greatest growth will be seen in the octogenarians and above with a 
greater than 100% increase anticipated by 2050 (Ethgen and Reginster 2004). It is not 
surprising then, that OA was deemed to be a signiﬁ  cant enough problem worldwide to 
prompt the World Health Organization (WHO) to designate 2000–2010 as the Bone 
and Joint Decade (Woolf and Pﬂ  eger 2003).
Not only is the burden of disease exempliﬁ  ed by the sheer numbers of people with 
the disease but also by the frequency of individual suffering. About 25% of persons 
over 55 experience knee pain most days of the month (Felson 2006). Utilizing joint pain 
as a marker of arthritis, 11% of Oxfordshire residents over 65 years of age surveyed Clinical Interventions in Aging 2007:2(4) 600
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reported hip and knee pain and 41% had hip or knee pain for 
at least a month (Dawson et al 2004).
Risk factors
There are some modiﬁ  able and nonmodiﬁ  able risk factors 
for OA. Under the age of 45 the risk of OA is more common 
in men. The risk rises and is more common in women after 
55 years of age. It is more likely to affect those with obesity; 
those with advancing age; and those with certain lifestyle 
issues such as sports interests like running and prior joint 
injuries; those with particular employment histories espe-
cially farming; and in some with genetic predisposition. OA 
of the hand may be more associated with inheritance than 
other joint presentations.
OA patterns vary along ethnic and cultural lines. Blacks 
from Jamaica, South Africa, Nigeria, and Liberia have lower 
hip OA prevalence compared with Europeans, as does the 
Asian population. OA can manifest in a single joint. How-
ever, when multiple joints are affected, everyday activities 
such as ambulation become more difﬁ  cult to perform as a 
result of the pain, swelling, and stiffness associated with the 
disease resulting in poorer quality of life outcomes (Keenan 
et al 2006). Chronic diseases in general result in impaired 
functioning across various physical, mental, and psychosocial 
parameters. Musculoskeletal conditions have been linked to 
poorer quality of life parameters than cardiovascular, neuro-
logic, endocrine, and renal diseases primarily as a result of 
physical impairment, disability, and poorer life satisfaction 
(Sprangers et al 2000).
Osteoarthritis not only affects the individual but has a 
signiﬁ  cant impact on healthcare costs, employer costs, and 
job performance. These are divided into direct and indirect 
costs. Direct costs attributable to arthritis include hospital 
and outpatient visits, pharmaceuticals, home health ser-
vices and assistive devices. In 75–79 year olds with OA, 
prescription drug costs were 102% higher than a similar 
cohort without the disease and their outpatient visits were 
more that doubled (Mapel et al 2004). Similar high costs 
were noted in this earlier trial for persons with a diagnosis 
of OA with increases seen in the areas of diagnostic testing, 
physician visits, and other direct medical costs. Prescriptions 
were substantially more signiﬁ  cant in those with OA than 
in those without this diagnosis (Gabriel et al 1997). Indirect 
costs include lost wages and work absences. During a two 
week period, workers ages 40–65 who experienced exacer-
bation of pain related to OA had more lost wages and time 
away from work than workers without exacerbations. These 
costs were estimated at over $7 billion per year. About 66% 
of this amount was attributed to only 38% of the surveyed 
workforce (Ricci et al 2005).
Glucosamine hydrochloride
One complementary medication that has been investigated for 
the treatment of OA is glucosamine. Glucosamine is a deriva-
tive of cellular glucose metabolism. It is also a component 
of glycosaminoglycans and proteoglycans of the cartilage 
matrix covering the ends of bones and hyaluronic acid which 
is a part of synovial ﬂ  uid within the joint. The primary source 
of exogenous glucosamine is the exoskeleton of shellﬁ  sh and 
exists in primarily two formulations, glucosamine hydrochlo-
ride (HCl) and glucosamine sulfate (Institute of Medicine 
and National Research Council 2005). Glucosamine sulfate 
requires compound stabilizers in the form of salts and has 
74% purity. Glucosamine HCl lacks the sulfate group and 
has 99% purity. Therefore, glucosamine HCl in a dosage of 
1,500 mg equals a dosage of 2,608 mg of glucosamine sulfate 
(Owens et al 2004). Glucosamine is readily absorbed from 
the gastrointestinal tract with oral administration, rapidly 
undergoes metabolism via the liver and the ﬁ  rst pass effect, 
and is eliminated through the feces and urine. Peak levels are 
in about 8 hours after oral ingestion primarily due to about 
90% protein binding (Anderson et al 2005).
The mechanism of action of glucosamine in humans is 
unknown. Because glucosamine is a part of the cartilage 
matrix in joint tissues, it has been theorized for many years 
that its administration could effect symptomatic relief for OA 
sufferers by supplying the components for cartilage repair and 
thus improve pain and disability. More recently, however, it 
has been demonstrated in animal models that glucosamine 
has an anti-inﬂ  ammatory effect via the reduction of nuclear 
factor kappa beta induced by interleukin-1 (IL-1) (Gouze 
et al 2002, 2006). A few studies in humans have revealed 
that glucosamine HCl reduces IL-1 stimulated production 
of catabolic enzymes and inﬂ  ammatory markers such as 
prostaglandin E2 by chondrocyte and synovial cells harvested 
from surgical specimens removed from patients with OA 
(Nakamura et al 2004; Uitterlinden et al 2006).
Literature review
For this review, the focus has been limited to the use of 
glucosamine HCl preparations for symptomatic relief 
of OA in humans. A Medline search was undertaken utilizing 
the search terms “glucosamine hydrochloride” and “osteo-
arthritis”. Secondary search terms were “human trials” and 
“ages 45 and older”. Studies were found that speciﬁ  ed the 
use of glucosamine HCl in humans were included. Other Clinical Interventions in Aging 2007:2(4) 601
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studies were reviewed and discarded because they focused 
on alternate preparations of glucosamine.
The most recent and largest randomized controlled trial 
(RCT) was a multi-center trial supported by the National Insti-
tute of Health, called the Glucosamine/chondroitin Arthritis 
Intervention Trial (GAIT). This study sought to evaluate 
glucosamine HCl, chondroitin sulfate, glucosamine HCl 
combined with chondroitin sulfate, celecoxib, or placebo for 
the pain associated with knee OA for a duration of 24 weeks. 
This study enrolled 1583 patients. Enrollees had to be at 
least 40 years of age, have suffered with knee pain for at least 
6 months, and have radiographic evidence of OA. The ﬁ  ve 
regimens studied were: 1) Glucosamine HCl 500 mg three 
times a day, 2) Chondroitin sulfate 400 mg three times a day, 
3) Glucosamine HCl 500 mg plus chondroitin sulfate 400 mg 
three times a day, 4) celecoxib 200 mg daily, or 5) placebo. 
Each of the ﬁ  ve groups had over 300 persons assigned and 
had a mean age of 59 years and a mean body mass index of 
32. Most of the participants, 64%, were women. Participants 
could take up to 4000 mg of acetaminophen as rescue medi-
cation per day, excluding the 24 hour period prior to clinical 
evaluation at 4, 8, 16, and 24 weeks.
The primary outcome measurement was a 20% decrease in 
the Western Ontario and McMaster Osteoarthritis (WOMAC), 
score from baseline to week 24, but secondary assessments 
included evaluation by the patient and evaluator of disease 
state and therapy response, changes in pain scores using the 
visual analog scale (VAS), quality of life assessed by the SF-
46 General Health Survey, and rescue medication use. The 
WOMAC Index is a 24 question validated survey assessing 
pain, function, and mobility. The VAS is a self-assessment of 
pain and function. Unlike other studies, the compounds used 
in this study were analyzed and certiﬁ  ed by the Food and 
Drug Administration. There was a withdrawal rate of about 
20% among all groups.
Overall, there was no difference among the treatment 
groups compared with placebo in a combined analysis for 
the primary outcome measure. Sub-group analysis was also 
performed. In the 78% of those with mild OA, there was 
no signiﬁ  cant change when compared with placebo for the 
4 therapy groups. Treatment effects ranged from a low of 63% 
response rate in the glucosamine HCl and chondroitin combi-
nation group to a high of 70% in the celecoxib group. None of 
these approached signiﬁ  cance however. In the moderate-to-
severe OA group (22% of participants), there was improve-
ment in the primary outcome measure, the WOMAC score, in 
the glucosamine HCl plus chondroitin sulfate treatment group 
at a P value of 0.002 when compared with placebo but there 
was no signiﬁ  cant improvement noted in the other therapy 
groups. Acetaminophen use was low among all groups. All 
groups had gradual improvement in pain over the 24 weeks but 
the celecoxib group had the fastest improvement at 4 weeks. 
The numbers of participants in the moderate-to-severe OA 
group was small (Clegg et al 2006).
An earlier study included 50 volunteers, ages 20 to 
70 years of age, experiencing knee pain and functional dis-
ability and evaluated glucosamine HCl in dosages of 2,000 mg 
per day compared with placebo over a 90 day period. Knee 
pain was assessed using The Knee Pain Scale and the 
Knee Injury and Osteoarthritis Outcome Score which have 
been designed to quantify knee pain and mobility. A complete 
history was taken from each participant regarding knee pain 
along with any prior evaluations and treatments received that 
might suggest cartilage degeneration. There were 46 subjects 
completing the study, 24 in the glucosamine group and 22 in 
the placebo group. The participants underwent four assess-
ment sessions and each time completed the two question-
naires, underwent joint line palpation, performed a “duck 
walk”, and climbed 32 stairs for 5 rotations. Of note, there 
were 15 people in the placebo arm that had greater than 
10 years of symptoms and only 7 in the glucosamine arm 
that had symptoms for more that 10 years. Otherwise the two 
groups were fairly evenly divided along gender and age 
lines. Prescription and anti-inﬂ  ammatory medications were 
allowed and recorded by the participants. Only 4 participants 
used anti-inﬂ  ammatory medications, one on a regular basis 
and 3 as rescue medications only. At week eight, those receiv-
ing glucosamine HCl had signiﬁ  cant improvement in pain 
and mobility (P = 0.004). By week twelve, 88% felt their 
pain had improved compared with only 17% of the placebo 
group. No signiﬁ  cant improvement between the groups was 
demonstrated with joint line palpation, “duck walk”, or stair-
climbing. Although subjective improvement was noted in 
this study, its signiﬁ  cance is questionable due to the small 
number of participants (Braham et al 2003).
Another study utilizing glucosamine HCl focused on 
patients with OA of the knee. The primary end point was a 
change in the WOMAC Index. A Likert Pain Scale was also 
administered to participants. Volunteers for the study were 
solicited via newspaper advertisements with 1100 responding 
and 118 meeting criteria for participation. Participants had to 
describe at least moderate knee pain for 6 months and have 
radiographic changes consistent with OA. They could not 
have used glucosamine previously or oral steroids. Subjects 
were given glucosamine HCl 500 mg to take three times a day 
which was provided by the manufacturer. Rescue medication Clinical Interventions in Aging 2007:2(4) 602
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was also permitted in the form of acetaminophen 500 mg 
that could be taken to a maximum of 4000 mg per day. One 
hundred one subjects completed the 8 week trial. Although 
improvements were seen in the glucosamine group in 23 of 
the 24 questions of the WOMAC, this was not statistically 
signiﬁ  cant from the placebo group. Improvements were sug-
gested however during the knee examination and documented 
in daily diaries by those given glucosamine. No differences 
were noted between the groups in acetaminophen use or side 
effect proﬁ  les (Houpt et al 1999).
An internet-based study was conducted by McAlindon 
and colleagues (2004) to evaluate the effectiveness of 
glucosamine for control of symptoms resulting from knee 
OA. The solicitation, interview, and selection of participants 
were entirely conducted over the internet. Participants had 
to be at least 45 years of age and have radiographic docu-
mentation consistent with joint space loss. Exclusion criteria 
included those using glucosamine, having a knee injection 
within 60 days, history of arthroplasty, or allergy to shellﬁ  sh. 
Initially the glucosamine utilized was a sulfate preparation. 
However during the trial, the manufacturer withdrew the 
supply and the preparation was changed to glucosamine 
HCl obtained from another pharmaceutical company. Two 
hundred ﬁ  ve participants were divided between the glucos-
amine and the placebo groups. There was an overall reduction 
in pain scores during the study among both groups but no 
signiﬁ  cant difference between the groups. Notably, there 
was a larger change in pain scored with the glucosamine 
HCl group than the glucosamine sulfate group but neither 
of the preparations signiﬁ  cantly improved pain when com-
pared with placebo. Even though assignment to groups was 
not standardized for gender, weight, or nonsteroidal anti-
inﬂ  ammatory drug (NSAID) use; the placebo group had 
more women, heavier participants as indicated by a higher 
body mass index, and used more NSAIDs; there remained 
no difference among the study groups when adjustments 
were made for these variables. Two important aspects of this 
study that may have affected the outcome have to do with it 
being solely internet based and utilization of two different 
compounds of glucosamine (McAlindon et al 2004).
Another study sought to determine the effectiveness of 
glucosamine in the reduction of pain in OA of the knee. 
Participants had to have a history of OA and radiographic 
ﬁ  ndings consistent with the disease. Ninety eight people ages 
34 to 81 were evenly assigned to the glucosamine and the 
placebo groups. Therapy consisted of glucosamine (prepara-
tion not speciﬁ  ed) 500 mg three times a day for 60 days. Other 
analgesics could be continued by participants as needed. 
Pain was assessed using the VAS while at rest and then 
while walking. There was no signiﬁ  cant difference between 
the mean scores of pain intensity between the two groups at 
rest or walking at 30 or 60 days. Glucosamine was found to 
be no more effective than placebo for relieving knee pain in 
this RCT (Rindone et al 2000).
Two RCTs evaluated the effect of a combination prod-
uct in degenerative joint disease (DJD) and OA of the knee 
and one also included DJD of the back. This combination 
included 1500 mg of glucosamine HCl, 1200 mg of chon-
droitin sulfate, and 228 mg of manganese ascorbate. In one 
of these RCTs, 34 male military personnel with knee or low 
back pain for 3 months and radiographic evidence of OA 
were included. Of the 21 knee participants, 20 met criteria 
for OA. This placebo-controlled crossover study was for 
a period of 16 weeks with only acetaminophen permitted 
as additional medication for pain. There was signiﬁ  cant 
improvement in knee symptoms. This was demonstrated by 
improvement in pain assessed by the VAS recorded at clinic 
visits and recorded in diaries, personal assessment of treat-
ment, and overall physical examination scores, but not the 
individual parameters of tenderness, effusion, swelling, and 
warmth. There was no signiﬁ  cant change noted between the 
medication and placebo arms in any of the other measured 
parameters of acetaminophen use, running, stair-climbing, 
and range of motion (Lefﬂ  er et al 1999).
In the other RCT, the same combination of nutraceuticals 
was used for the treatment of participants with knee OA, but 
the dosage was 2000 mg of glucosamine HCl, 1600 mg of 
chondroitin sulfate, and 304 mg of manganese ascorbate per 
day in divided doses. Participants were followed for 6 months 
and evaluated every two months using the validated Lequesne 
questionnaire of disease severity, with a 25% decrease in this 
measurement as the primary outcome. Secondary measures 
were the WOMAC questionnaire and the patient’s own global 
assessment of their OA using the visual analog scale. Rescue 
medications allowed included NSAIDs and acetaminophen. 
Eligible participants were 45–75 years of age and 93 were 
accepted for inclusion. There were 46 in the treatment arm 
and 47 received placebos. Mild or moderate OA was present 
in 33 of those receiving medication and 39 receiving 
placebo and severe OA in 13 and 8 in treatment and placebo 
arms respectively. There was improvement noted in those 
with mild and moderate OA with treatment intervention 
at 52% compared with 28% with placebo at four and six 
months only. There was no difference with intervention or 
placebo in those with severe knee OA, either group when 
assessed with the WOMAC questionnaire for assessment of Clinical Interventions in Aging 2007:2(4) 603
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pain, function, and joint stiffness, or patients’ assessments 
of response. The reduction in acetaminophen use from 
2 to 6 months approached but did not reach signiﬁ  cance. 
Of note, this study was sponsored in part by the manufacturer 
of the glucosamine, chondroitin, and manganese ascorbate 
product (Das and Hammad 2000).
Adverse events
Side-effects and adverse events related to glucosamine HCl 
were mild and fairly consistent across all studies. Primarily 
side-effects were related to the gastrointestinal tract and 
included dyspepsia, nausea, vomiting, diarrhea, and 
constipation. Other effects include headache, bad taste, 
and fatigue. More serious events reported included the onset 
of diabetes, hypothyroidism, peripheral edema, sexual 
dysfunction, elevated blood pressure, and chest pain. Most 
side effects did not require discontinuation of therapy or 
withdrawal from the study; however, a few were unable to 
tolerate the symptoms and did withdraw (Houpt et al 1999; 
Lefﬂ  er et al 1999; Das and Hammad 2000; Rindone et al 
2000; McAlindon et al 2004; Clegg et al 2006). There are no 
long term studies of side-effects, adverse events, or toxicity 
of glucosamine HCl.
Conclusion
Osteoarthritis, particularly of the hip and knee, can severely 
affect the health and well-being of those who suffer with the 
disease. The population of the world is aging and so is the 
burden of disease of OA. In those afﬂ  icted with the disease, a 
majority of the disease burden will be in those over 65 years 
of age. A substantial amount of the healthcare dollars spent 
for OA involves direct costs that are associated with outpa-
tient evaluation, treatment modalities especially medications, 
and assistive services and equipment. Indirect costs can 
also be enormous when including lost time from work and 
associated lost wages.
Not only because of the economic burden of OA but 
also because of the poor health outcomes and quality of life 
experienced by those with the disease and with advancing 
symptoms with age, therapies to reduce symptoms especially 
pain exacerbations, improve quality of life, and perhaps 
slow the progression of the disease are being explored. 
Other beneﬁ  ts would be if the therapy had few side effects, 
were minor in nature, and was reasonably priced and read-
ily available. One such potential modality is glucosamine. 
Initial studies for this therapy were done in Europe more than 
30 years ago and were sponsored by the glucosamine manu-
facturers. The studies lacked standardized randomization, 
standardization of medication compounding, and suffered 
from poor masking of participants and most did not adhere 
to the intention-to-treat analysis of data. However, many of 
these initial studies demonstrated improvement in pain and 
function in the glucosamine therapy groups when compared 
with placebo or at times to a particular NSAID.
Because of these initial positive outcomes, additional 
studies have been undertaken to remove some of the initial 
biases and to attempt to duplicate the results. There is little 
data on glucosamine HCl since most studies have utilized 
glucosamine sulfate and not glucosamine HCl. Only one of 
the RCTs reviewed in this article demonstrated any signiﬁ  -
cant improvement in outcomes with glucosamine HCl alone 
over placebo or NSAID. Some studies did suggest improve-
ment but the results were not statistically signiﬁ  cant.
In the largest, most talked about and awaited trial, the 
GAIT trial, the results were confusing and difﬁ  cult to inter-
pret. Statistically signiﬁ  cant improvement was seen only in 
those with moderate-to-severe knee OA with the combina-
tion therapy of glucosamine HCl and chondroitin sulfate; 
however, only small numbers of subjects were involved. 
Another combination product of glucosamine HCl, chon-
droitin sulfate, and manganese ascorbate was compared with 
placebo in two earlier RCTs and improvement in pain and 
function were seen in those with mild-to-moderate OA.
In conclusion, this current review of the available literature 
suggests little beneﬁ  t with the use of glucosamine HCl alone 
to those suffering from OA. Certain combination products 
may be of beneﬁ  t in selected subgroups of patients.
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